Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia

Expert Opinion on Drug Metabolism & Toxicology
Vidya PereraAndrew J McLachlan

Abstract

Schizophrenia, a mental disorder, is a debilitating condition which typically strikes young people in their early 20's. Antipsychotic medications are widely prescribed for the treatment of schizophrenia however a balancing act is necessary to provide the correct dose to each patient. It is suggested that a large number of patients discontinue antipsychotic pharmacotherapy because the treatments provided do not always reduce the positive symptoms of the disease, while many have adverse effects on the patients. This implies that neither the incorrect drug nor the optimal dosage for that patient is achieved. The current review investigates variability in response to olanzapine with a specific focus on the common intrinsic and extrinsic factors that influence both olanzapine and CYP1A2 activity. Furthermore, the authors discuss the utilization of phenotyping and genotyping of CYP1A2 and their potential utility in clinical practice for olanzapine dosing regimens. The authors also consider the potential of pharmacometrics compared to pharmacogenomics as a tool to personalize medicine. Careful consideration must be given to the impact of a genetic variant on the disposition of a drug prior to implementing genetic 'tests' to determine ...Continue Reading

References

Dec 1, 1992·Clinical Pharmacology and Therapeutics·M V RellingW E Evans
Nov 1, 1991·Clinical Pharmacology and Therapeutics·W Kalow, B K Tang
Mar 1, 1991·Trends in Pharmacological Sciences·W Kalow
Jul 1, 1990·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M H Skinner
Jan 1, 1989·European Journal of Clinical Pharmacology·H WietholtzS Matern
Jan 1, 1985·European Journal of Clinical Pharmacology·D R Abernethy, E L Todd
May 1, 1983·Clinical Pharmacology and Therapeutics·D M GrantW Kalow
Mar 1, 1995·British Journal of Clinical Pharmacology·H R HaF Follath
Jan 1, 1995·European Journal of Clinical Pharmacology·A CatteauC Bonaïti-Pellie
Jan 1, 1995·Clinical Pharmacology and Therapeutics·C M MasimirembwaW Kalow
Nov 1, 1994·British Journal of Clinical Pharmacology·L BertilssonJ Benitez
May 1, 1994·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·K L SalyersI G Sipes
Feb 1, 1994·Clinical Pharmacokinetics·D R Krishna, U Klotz
Sep 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·H K KroemerM Eichelbaum
May 1, 1993·Clinical Pharmacology and Therapeutics·W Kalow, B K Tang
Jun 1, 1996·British Journal of Clinical Pharmacology·J A Carrillo, J Benitez
Aug 1, 1996·Clinical Pharmacology and Therapeutics·J A CarrilloL Bertilsson
Mar 1, 1997·British Journal of Clinical Pharmacology·B B Rasmussen, K Brøsen
Mar 1, 1997·Journal of Toxicology and Environmental Health·D Hoffmann, I Hoffmann
May 7, 1997·Journal of Theoretical Biology·M Mahner, M Kary
Jun 1, 1997·Clinical Pharmacology and Therapeutics·L BecquemontP Jaillon
Mar 10, 1998·British Journal of Clinical Pharmacology·A C ParkerI Choonara
Aug 5, 1998·British Journal of Clinical Pharmacology·M NakajimaY Kuroiwa
Nov 13, 1998·The American Journal of Psychiatry·G W DalackJ H Meador-Woodruff
Dec 22, 1998·European Journal of Clinical Pharmacology·R A LucasR F Bergstrom
Jul 31, 1999·Clinical Pharmacokinetics·S Zevin, N L Benowitz
Oct 8, 1999·Clinical Pharmacokinetics·J T CallaghanC M Beasley

Citations

Aug 25, 2015·Current Treatment Options in Psychiatry·Daniel C Javitt
Aug 17, 2018·Acta Psychiatrica Scandinavica·M Na TakuathungN Koonrungsesomboon
Aug 21, 2018·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Manuel A Franco-MartinMaría Isidoro-García
Apr 30, 2014·British Journal of Clinical Pharmacology·Vidya PereraA Forrest
Sep 3, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vidya PereraAndrew J McLachlan
Aug 5, 2014·Therapeutic Drug Monitoring·Fabian CzerwenskyWerner Steimer
Jan 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Steven L Dubovsky
Dec 2, 2017·British Journal of Clinical Pharmacology·Thomas M PolasekAndrew Rowland
Jan 24, 2021·Archives of Pharmacal Research·Yeo-Jung KwonYoung-Jin Chun

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here